Citius Oncology Shareholders Approve Directors and Auditor
TipRanks (Tue, 29-Sep 5:01 PM ET)
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
PRNewswire (Thu, 3-Sep 8:30 AM ET)
PRNewswire (Fri, 14-Aug 4:30 PM ET)
PRNewswire (Fri, 14-Aug 4:30 PM ET)
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
PRNewswire (Wed, 12-Aug 8:01 AM ET)
Citius Oncology's LYMPHIR Gains Strong Institutional Traction as New Accounts Jump 78%
Market Chameleon (Wed, 5-Aug 7:47 AM ET)
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
PRNewswire (Wed, 5-Aug 9:17 AM ET)
PRNewswire (Tue, 21-Jul 9:17 AM ET)
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
Citius Oncology trades on the NASDAQ stock market under the symbol CTOR.
As of October 2, 2026, CTOR stock price declined to $0.95 with 206,661 million shares trading.
CTOR has a beta of 4.28, meaning it tends to be more sensitive to market movements. CTOR has a correlation of 0.28 to the broad based SPY ETF.
CTOR has a market cap of $100.47 million. This is considered a Micro Cap stock.
Last quarter Citius Oncology reported $1 million in Revenue and -$.08 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.01.
The top ETF exchange traded funds that CTOR belongs to (by Net Assets): VTI, VXF.
CTOR has underperformed the market in the last year with a price return of -49.5% while the SPY ETF gained +16.1%. However, in the short term, CTOR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +39.6% vs +3.6% return in SPY. But in the last 2 weeks, CTOR shares have been beat by the market, returning -16.7% compared to an SPY return of +1.0%.
CTOR support price is $.91 and resistance is $1.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTOR shares will trade within this expected range on the day.
